Download PDFPDF
Ischaemia modified albumin cannot be used for rapid exclusion of acute coronary syndrome
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Normalization of ischemia modified albumin results for serum albumin.
    • Giuseppe Lippi, Director
    • Other Contributors:
      • Rosalia Aloe, Martina Montagnana and Gianfranco Cervellin

    Ischemia modified albumin (IMA) has recently been proposed for the early detection of myocardial ischemia without infarction [1]. We read with interest the article of Ming-Hui Lin, who evaluated this marker as an early negative predictor of acute coronary syndrome (ACS) in different time to presentation groups and different cardiac risk groups [2]. The authors asserted that IMA is a relatively new test, performed on diffe...

    Show More
    Conflict of Interest:
    None declared.